An interventional study of Start Antibiotics / Continue Antibiotics for treatment of bacteriuria and No Antibiotics for treatment of bacteriuria in Infectious Disease, sponsored by Mount Sinai Hospital, Canada. Recruiting at 7 sites in 2 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Mount Sinai Hospital, Canada · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Communicable Diseases with a site in Canada — 7 open to participants now, 8 under way, 2 of them phase 3. Communicable Diseases · Canada.
Among the 34 studies in Communicable Diseases with a site in Canada, this one is the 9th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2024, is one of 12 with no phase, and was the 28th registered.
628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.
Browse Communicable Diseases studies →7 of the 34 studies in Communicable Diseases with a site in Canada are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in Canada, United States, France and 3 more countries
Ages 18–65
McGill University · Sites in Canada
Ages 18+
University of Calgary · Sites in Canada
Ages 37 wk+ · Healthy volunteers
Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Sites in Canada
Population Health Research Institute · Sites in Canada, Argentina, Bangladesh and 22 more countries
Ages 35–70
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is above the median of 89 across 381 interventional studies indexed under Communicable Diseases.
Median enrollment 125 across the 26 interventional studies, 678 across the 8 observational. Of the 20 that completed or were terminated, 6 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 34 have an industry lead sponsor. The 10 most frequent:
Mount Sinai Hospital, Canada is the lead sponsor of 158 studies on the registry; 32 are open to participants now.
Mount Sinai Hospital, Canada has 3 studies filed under Communicable Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Communicable Diseases with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04992104The Hospital for Sick ChildrenMicrobiome and Malnutrition in Pregnancy | 2027-03 |
| NCT07095192McGill UniversityScaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada | 2027-06-20 |
| NCT06004739Mount Sinai Hospital, CanadaAntibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection | 2027-09 |
| NCT07654283AusperBio Therapeutics Inc.Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | 2027-11-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Communicable Diseases with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Delirium is an acute confusional state that is experienced by many older adults who are admitted to hospital. To treat delirium the underlying cause needs to be identified promptly, but this is challenging. One of the potential causes of delirium is infection. Urine tests show that most patients experiencing delirium have bacteria in their urine, however, bacteria in the urine is common among older adults, and does not automatically indicate an infection is present. As a result it is difficult to know whether a lower urinary tract infection is present as individuals with delirium are frequently unable to report clinical signs of infection - symptoms of pain or discomfort with urination, having to urinate more frequently or pelvic discomfort. Very often, individuals with delirium are treated with antibiotics despite the fact that it is unknown whether antibiotics help to improve delirium in cases where bacteria in the urine is present. This proposed study is a randomized controlled trial that will examine if adults (age 60 or older) with delirium and suspected infection benefit from taking antibiotics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Participants will be randomized to start or continue with antibiotics. Antibiotic type and duration targeted to lower urinary tract infection as directed by the Most Responsible Physician (MRP).
Drug: Start Antibiotics / Continue Antibiotics for treatment of bacteriuria
Participants will be randomized to no antibiotics
Other: No Antibiotics for treatment of bacteriuria
Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician \[MRP\]). Antibiotics choice to be selected by the MRP.
Participants will be randomized to no antibiotics
Delirium at day 7 or at day of hospital discharge, whichever is earliest
Delirium will be assessed using Confusion Assessment Method (CAM). CAM assesses 4 delirium features: \[1\] inattention, \[2\] acute and fluctuating level of consciousness, \[3\] disorganized thinking and \[4\] altered mental status. For a diagnosis of delirium by CAM, the patient must display feature \[1\] AND \[2\], AND EITHER \[3\] or \[4\].
Time frame: Delirium will be assessed at the first of day 7 or discharge
Length of hospitalization
Time frame: Up to 30 days
Number of participants with bacteremia (bacteria isolated in blood culture)
Time frame: Up to 7 days
Number of participants who were transferred to Intensive Care Unit (ICU)
Time frame: Up to 7 days
Number of participants who had a fall
Time frame: Up to 7 days
Number of participants who were physically restrained
Time frame: Up to 7 days
Number of participants who received antipsychotics
Time frame: Up to 7 days
Days of antibiotics
Time frame: Up to 7 days
Number of participants with C. difficile infection
C. difficile will be defined as a combination of a positive microbiological test for C. difficile (if still hospitalized at the time of diagnosis), or self-reported diagnosis of C. difficile (provided the patient reported diarrhea and receipt of an antibiotic to treat C. difficile)
Time frame: By 30 days
Number of participants who died
Time frame: By 30 days
Number of participants who died
Time frame: By 365 days
Number of participants who were readmitted to hospital
Time frame: By 365 days
Number of participants who were readmitted to hospital
Time frame: By 30 days
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Sep 2027, 40 months after the start.
Of 128 non-industry interventional studies with no phase under Communicable Diseases, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 40 months is above that.
Counting every sponsor, half of 144 studies reached it within 21 months; a quarter within 6 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mount Sinai Hospital, Canada →